Rhenovia opens biosimulation platform for CNS drug discovery

Rhenovia Pharma, a Mulhouse, France-based biopharmaceutical company specialized in the development and optimization of treatments for  Alzheimer's and other diseases of the brain, is offering its first  biosimulation platform for use in collaborative projects to optimize  drugs targeting diseases of the central nervous system.

The Rhenovia platform is being made available as part of the company's  RHEDDOS program. Developed over the last three years the platform,  RHENOMS SYNAPSE, is one of the most advanced systems that exploit the  complexity of biology systems and the multifactorial nature of brain  diseases. The platform models synaptic transmission and simulates brain  functions, such as learning and memory, and their pathological states.  It works by integrating elementary models of molecular processes taking  place at individual synapses and incorporating them into a global model  of synaptic transmission.